Form 4: Korro Bio Director Nessan Bermingham Granted Stock Options Valued at $14.87 Per Share

Korro Bio, Inc. Director Nessan Bermingham was granted 6,010 stock options with an exercise price of $14.87 per share, vesting on the earlier of the one-year anniversary of the grant or the next annual stockholders' meeting.

Summary

• Korro Bio, Inc. Director Nessan Bermingham was granted 6,010 stock options on June 11, 2025.
• The exercise price for these stock options is $14.87 per share.
• The options will vest in full on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders, subject to continued service as a non-employee director.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Nessan Bermingham beneficially owns 6,010 derivative securities (stock options) directly.
• A Limited Power of Attorney, dated March 12, 2025, was granted by Nessan Bermingham to designated attorneys-in-fact for executing SEC filings on his behalf.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard compensation practices and aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, as the options gain value if the company's stock price increases.
• It represents a form of compensation for the director's continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding the company's future performance or operations, beyond the vesting schedule of the granted options.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across industries, including the biotechnology sector, to attract and retain talent and align management interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The grant of 6,010 stock options to Nessan Bermingham, a director of Korro Bio, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options represents potential future dilution if exercised, but also aims to align the director's incentives with shareholder value creation.
• Director (Nessan Bermingham): Receives equity compensation, providing a direct financial interest in the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Korro Bio, KRRO, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Beneficial Ownership, Equity Compensation, Biotechnology